Trial reportJournal of cosmetic dermatology2025
Intertrigo in Severe Obesity: Clinical Insights and Outcomes With a New Antimicrobial Silver-Infused Breathable Fabric.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Skin as a Metabolic Organ: Dermatologic Markers of Morbid Obesity and Their Role in Risk Stratification and Treatment Monitoring.Diagnostics (Basel, Switzerland) · 2026Review
- Recognising obesity-related skin conditions in general practice: a practical guide.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIntertrigo is often underdiagnosed in obesity.
objectivesTo investigate the incidence of intertrigo in obesity and assess the efficacy of a moisture-wicking fabric (MWF) with antimicrobial silver.
methodsIntertrigo symptoms were evaluated in patients with severe obesity, and the effect of MWF application was assessed in a subset of these patients after 5 or 10 days of use.
resultsIn inpatients with obesity (n = 2.778, mean age 63.9 ± 13.3 years, BMI 43.4 ± 6.8 kg/m
conclusionsWe underline the need for intertrigo screening in patients with obesity, especially in those with risk factors, such as female, older, and higher BMI. The use of a novel MWF effectively alleviates symptoms within a short treatment period and should be considered as an optional intertrigo treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.